AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Antigenics presents positive clinical data of personalized cancer vaccine trials.(Brief Article)
2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Antigenics Inc. (AGEN) announced interim results of five clinical trials, including three evaluating the company's personalized cancer vaccine Oncophage (HSPPC-96) in the treatment of melanoma, gastric and colorectal cancers. The phase I and II studies demonstrated that patients treated with Oncophage experienced clinical and immunological response. Findings were presented at the 38th annual meeting of the American Society of Clinical Oncology (ASCO).
"In all cancers and species evaluated to date, we have observed a consistent, tumor-specific response associated with Oncophage treatment," said Jonathan Lewis, MD, PhD, chief medical officer of Antigenics. "These latest data show that the mechanism of immune response appears to be virtually identical in melanoma, gastric and colorectal cancers. With each trial, support continues to grow for the potential utility of Oncophage in a multitude of malignancies."
Oncophage is a personalized cancer treatment that is derived from each individual's tumor. Containing the "antigenic fingerprint" of the patient's particular cancer, it is designed to reprogram the body's immune system to target and destroy only cancer cells bearing this fingerprint. Oncophage is intended to leave healthy tissue unaffected to prevent the debilitating side effects associated with traditional cancer treatments. Currently in phase III trials for kidney cancer and melanoma, clinical research evaluating Oncophage includes studies in several other cancers such as lymphoma and pancreatic cancer.
Among the data presented at the ASCO meeting were updated results from a phase II study in metastatic stage IV melanoma. The 39-patient trial demonstrated that Oncophage treatment is associated with both clinical and immune response. Fourteen patients reacted favorably to Oncophage, including two patients who experienced complete disease regression, three patients with long-term (>5 months) disease stabilization, and four who remained disease-free for up ...
- Phase II Results of Antigenics' Oncophage Cancer Vaccine in Colorectal Cancer...
- Press release article from: Business Wire August 19, 2003 700+ words
...was followed by two cycles of Oncophage treatment for all patients. Researchers determined that immune response to Oncophage vaccination is...demonstrated immune response to Oncophage treatment also experienced a significantly...
- Phase II results of cancer vaccine considered "encouraging".
- Newspaper article from: Health & Medicine Week September 15, 2003 700+ words
...was followed by two cycles of Oncophage treatment for all patients. Researchers determined that immune response to Oncophage vaccination is...demonstrated immune response to Oncophage treatment also experienced a significantly...
- Data from Investigator-Sponsored Trial of Oncophage(R) Cancer Vaccine in Glioma...
- Press release article from: Business Wire October 25, 2007 700+ words
...Months Cancer-Specific Immune Response Demonstrated in All...patients were monitored for immune response before and after Oncophage treatment. According to investigators...A tumor-specific immune response was detected in all...
- Data From Investigator-Sponsored Trial of Oncophage(R) Cancer Vaccine in Glioma...
- Press release article from: PR Newswire November 16, 2006 700+ words
...associated with tumor- specific immune response in six treated patients...Patients are monitored for immune response before and after Oncophage treatment. In the first cohort, tumor-specific immune response was detected after vaccination...
- Final Data From Phase 1 Investigator-Sponsored Trial of Oncophage[R] Cancer...
- Press release article from: Business Wire November 24, 2008 700+ words
...evoked a tumor-specific immune response by producing activated...Patients were monitored for immune response before and after Oncophage treatment using three different...vaccine. A tumor-specific immune response was detected after vaccination...
- The Immune Response Corporation Evaluates a Second-Generation HIV Vaccine...
- Press release article from: Business Wire July 9, 2003 700+ words
...BUSINESS WIRE)--July 9, 2003 The Immune Response Corporation (Nasdaq:IMNR) and...HYBN.OB) today announced that The Immune Response Corporation is conducting preclinical...generation vaccine would be based on The Immune Response Corporation's whole-killed HIV...
- The Immune Response Corporation Initiates a Preclinical Development Program...
- Press release article from: PR Newswire November 3, 2003 700+ words
The Immune Response Corporation announced today that...BULLETIN BOARD: HYBN) to enhance the immune response to a vaccine antigen, with the...Phase II clinical trials by The Immune Response Corporation for the treatment of...
- Immune Response Stock Dips After Study.(securities information)(Brief...
- Magazine article from: San Diego Business Journal WEBB, MARION November 13, 2000 700+ words
Shares of Immune Response Corp. continued to hover in the...expectations. "The issue is, (Immune Response) had a high-risk drug and did...Remune. McCamant, however, said Immune Response has made a mistake by alienating...
